Newron Pharmaceuticals Shares Owned By Insiders vs. Cash And Equivalents
| NWRN Stock | CHF 8.82 0.32 3.76% |
For Newron Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Newron Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Newron Pharmaceuticals SpA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Newron Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Newron Pharmaceuticals SpA over time as well as its relative position and ranking within its peers.
Newron |
Newron Pharmaceuticals Cash And Equivalents vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Newron Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Newron Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Newron Pharmaceuticals SpA is regarded fourth in shares owned by insiders category among its peers. It is considered to be number one stock in cash and equivalents category among its peers creating about 11,893,145 of Cash And Equivalents per Shares Owned By Insiders. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Newron Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Newron Cash And Equivalents vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Newron Pharmaceuticals |
| = | 4.96 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Newron Pharmaceuticals |
| = | 58.99 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Newron Cash And Equivalents Comparison
Newron Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Newron Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Newron Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Newron Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Newron Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Newron Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company was founded in 1998 and is headquartered in Bresso, Italy. NEWRON PHARMA operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 24 people.
Newron Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Newron Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Newron Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Newron Pharmaceuticals' important profitability drivers and their relationship over time.
Use Newron Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Newron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Newron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Newron Pharmaceuticals Pair Trading
Newron Pharmaceuticals SpA Pair Trading Analysis
The ability to find closely correlated positions to Newron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Newron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Newron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Newron Pharmaceuticals SpA to buy it.
The correlation of Newron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Newron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Newron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Newron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Newron Pharmaceuticals position
In addition to having Newron Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Iron Thematic Idea Now
Iron
Companies involved in production of steel and iron. The Iron theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Iron Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Newron Stock Analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.